A-D-Beadell Investment Counsel Trimmed Johnson & Johnson (JNJ) Holding; ADYNXX (ADYX) SI Decreased By 67.09%

Johnson & Johnson (NYSE:JNJ) Logo

ADYNXX INC (OTCMKTS:ADYX) had a decrease of 67.09% in short interest. ADYX’s SI was 13,100 shares in September as released by FINRA. Its down 67.09% from 39,800 shares previously. With 28,900 avg volume, 1 days are for ADYNXX INC (OTCMKTS:ADYX)’s short sellers to cover ADYX’s short positions. The stock increased 96.20% or $1.77 during the last trading session, reaching $3.61. About 532 shares traded. Adynxx, Inc. (OTCMKTS:ADYX) has declined 63.61% since September 16, 2018 and is downtrending. It has underperformed by 63.61% the S&P500.

A-D-Beadell Investment Counsel Inc decreased Johnson & Johnson (JNJ) stake by 40.88% reported in 2019Q2 SEC filing. A-D-Beadell Investment Counsel Inc sold 10,536 shares as Johnson & Johnson (JNJ)’s stock declined 8.26%. The A-D-Beadell Investment Counsel Inc holds 15,240 shares with $2.12 million value, down from 25,776 last quarter. Johnson & Johnson now has $345.15 billion valuation. The stock increased 0.27% or $0.35 during the last trading session, reaching $130.78. About 4.49 million shares traded. Johnson & Johnson (NYSE:JNJ) has declined 1.48% since September 16, 2018 and is downtrending. It has underperformed by 1.48% the S&P500. Some Historical JNJ News: 27/03/2018 - Johnson & Johnson CDS Widens 5 Bps, Most in 23 Months; 27/03/2018 - FDA: Johnson & Johnson Consumer, Inc.- Johnson & Johnson BAND-AID® Brand First Aid Products SECURE-FLEX® Wrap (size: 3in); 17/04/2018 - J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout $JNJ; 29/05/2018 - Novo Nordisk’s oral diabetes drug beats Jardiance in study; 17/04/2018 - JNJ RESTRUCTURING DRIVEN BY NEW TECHNOLOGY FOR NEWER PRODUCTS; 17/04/2018 - J&J - U.S. TAX LEGISLATION PASSED LAST YR IS CREATING OPPORTUNITY TO INVEST MORE THAN $30 BLN IN R&D, CAPITAL INVESTMENTS IN U.S. OVER NEXT 4 YRS; 11/04/2018 - J&J, lmerys must pay $80 mln punitive damages in case linking cancer to asbestos in talc; 16/03/2018 - J&J - TRANSACTION WAS CONTEMPLATED IN COMPANY’S GUIDANCE PROVIDED ON JANUARY 23, 2018; 22/05/2018 - J&J Re-Launches Baby Care Line Amid Growing Consumer Concerns About Cancer-Causing Talc; 07/03/2018 - IFM Therapeutics and Bristol-Myers Squibb Awarded 2017 Deal of the Year by Clarivate Analytics

Since June 11, 2019, it had 1 insider buy, and 0 selling transactions for $419,040 activity. $419,040 worth of stock was bought by HEWSON MARILLYN A on Tuesday, June 11.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Finance.Yahoo.com which released: “An Intrinsic Calculation For Johnson & Johnson (NYSE:JNJ) Suggests It’s 43% Undervalued - Yahoo Finance” on September 09, 2019, also Finance.Yahoo.com with their article: “3 Days Left Until Johnson & Johnson (NYSE:JNJ) Trades Ex-Dividend - Yahoo Finance” published on August 22, 2019, Finance.Yahoo.com published: “Will Lawsuits Sink Johnson & Johnson Stock? - Yahoo Finance” on August 23, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “J&J gains after opioid ruling - Seeking Alpha” published on August 26, 2019 as well as Finance.Yahoo.com‘s news article titled: “After Hours: Johnson & Johnson Loses Opioid Case, Amazon Allegedly Loses Top Executive - Yahoo Finance” with publication date: August 26, 2019.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on October, 15. They expect $2.00 EPS, down 2.44% or $0.05 from last year’s $2.05 per share. JNJ’s profit will be $5.28B for 16.35 P/E if the $2.00 EPS becomes a reality. After $2.58 actual EPS reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -22.48% negative EPS growth.

Among 5 analysts covering Johnson & Johnson (NYSE:JNJ), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Johnson & Johnson has $157 highest and $140 lowest target. $148.80’s average target is 13.78% above currents $130.78 stock price. Johnson & Johnson had 11 analyst reports since March 25, 2019 according to SRatingsIntel. The company was maintained on Wednesday, April 17 by Raymond James. Credit Suisse maintained Johnson & Johnson (NYSE:JNJ) rating on Thursday, May 16. Credit Suisse has “Outperform” rating and $15600 target. The stock of Johnson & Johnson (NYSE:JNJ) has “Equal-Weight” rating given on Tuesday, August 27 by Morgan Stanley. As per Friday, June 21, the company rating was initiated by Barclays Capital. The rating was maintained by Raymond James with “Outperform” on Wednesday, July 17. The stock of Johnson & Johnson (NYSE:JNJ) has “Equal-Weight” rating given on Wednesday, April 17 by Morgan Stanley. Credit Suisse maintained the stock with “Outperform” rating in Wednesday, April 17 report. The stock of Johnson & Johnson (NYSE:JNJ) earned “Outperform” rating by BMO Capital Markets on Wednesday, April 17. The stock has “Buy” rating by Raymond James on Monday, March 25.

Investors sentiment increased to 0.88 in 2019 Q2. Its up 0.04, from 0.84 in 2019Q1. It increased, as 48 investors sold JNJ shares while 813 reduced holdings. 126 funds opened positions while 628 raised stakes. 1.83 billion shares or 0.48% less from 1.84 billion shares in 2019Q1 were reported. Merriman Wealth Mngmt Ltd has 0% invested in Johnson & Johnson (NYSE:JNJ). Sandy Spring Bancorporation has 1.44% invested in Johnson & Johnson (NYSE:JNJ) for 128,697 shares. First Business Fincl reported 5,093 shares or 0.12% of all its holdings. Cambridge has invested 2.15% in Johnson & Johnson (NYSE:JNJ). Windsor Mngmt Limited Liability invested 0.58% of its portfolio in Johnson & Johnson (NYSE:JNJ). Blair William Il holds 789,325 shares. Harbour Investment Management Limited Liability Co, Washington-based fund reported 18,163 shares. Cardinal Mngmt holds 1.79% or 129,056 shares in its portfolio. Everence Cap invested in 1.54% or 66,751 shares. Everett Harris Ca holds 796,274 shares. Harding Loevner LP invested in 800 shares or 0% of the stock. Somerset Group Ltd Liability has invested 0.28% of its portfolio in Johnson & Johnson (NYSE:JNJ). 29,782 were reported by Garrison Asset Mngmt Ltd Com. Kemnay Advisory Incorporated invested 0.02% of its portfolio in Johnson & Johnson (NYSE:JNJ). Davy Asset Management owns 67,280 shares or 3.03% of their US portfolio.

More notable recent Adynxx, Inc. (OTCMKTS:ADYX) news were published by: Seekingalpha.com which released: “Adynxx readies $15M stock offering - Seeking Alpha” on August 22, 2019, also Seekingalpha.com with their article: “Adynxx down 38% on Nasdaq delisting - Seeking Alpha” published on June 12, 2019, Seekingalpha.com published: “Adynxx sets May 29 as payment date of special cash dividend - Seeking Alpha” on May 10, 2019. More interesting news about Adynxx, Inc. (OTCMKTS:ADYX) were released by: Seekingalpha.com and their article: “Intrexon and Enlivex Therapeutics among healthcare gainers; ContraVir Pharmaceuticals leads the losers - Seeking Alpha” published on June 18, 2019 as well as Seekingalpha.com‘s news article titled: “With Favorable Shift In Advance Wound Care Market, Alliqua Could Grow Revenues To $35M Within 3 Years - Seeking Alpha” with publication date: April 04, 2014.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.